Craig C. Hopkinson Alkermes Plc. (ALKS) insider trading activity

Craig C. Hopkinson is EVP R&D, Chief Medical Officer of Alkermes plc.. Currently has a direct ownership of 109,709 shares of ALKS, which is worth approximately $2.82 Million. The most recent transaction as insider was on Feb 23, 2024, when has been sold 3,414 shares (Ordinary Shares) at a price of $29.57 per share, resulting in proceeds of $100,951. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 110K

0% 3M change

93.97% 12M change

Total Value Held $2.82 Million

Craig C. Hopkinson Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 23 2024	SELL Payment of exercise price or tax liability	$100,951 $29.57 p/Share	3,414 Reduced 3.02%	109,709 Ordinary Shares
Feb 23 2024	BUY Exercise of conversion of derivative security	-	7,689 Added 6.36%	113,123 Ordinary Shares
Feb 22 2024	SELL Payment of exercise price or tax liability	$157,617 $28.91 p/Share	5,452 Reduced 4.92%	105,434 Ordinary Shares
Feb 22 2024	BUY Exercise of conversion of derivative security	-	12,278 Added 9.97%	110,886 Ordinary Shares
Feb 20 2024	SELL Payment of exercise price or tax liability	$138,943 $30.39 p/Share	4,572 Reduced 4.43%	98,608 Ordinary Shares
Feb 20 2024	BUY Exercise of conversion of derivative security	-	10,297 Added 9.07%	103,180 Ordinary Shares
Feb 18 2024	SELL Payment of exercise price or tax liability	$127,143 $32.18 p/Share	3,951 Reduced 4.08%	92,883 Ordinary Shares
Feb 18 2024	BUY Exercise of conversion of derivative security	-	8,897 Added 8.41%	96,834 Ordinary Shares
Feb 08 2024	SELL Payment of exercise price or tax liability	$409,045 $26.77 p/Share	15,280 Reduced 14.8%	87,937 Ordinary Shares
Feb 08 2024	BUY Grant, award, or other acquisition	-	46,658 Added 31.13%	103,217 Ordinary Shares
Feb 22 2023	SELL Payment of exercise price or tax liability	$148,430 $27.77 p/Share	5,345 Reduced 8.63%	56,559 Ordinary Shares
Feb 22 2023	BUY Exercise of conversion of derivative security	-	12,038 Added 16.28%	61,904 Ordinary Shares
Feb 21 2023	SELL Payment of exercise price or tax liability	$84,781 $27.77 p/Share	3,053 Reduced 5.77%	49,866 Ordinary Shares
Feb 21 2023	BUY Exercise of conversion of derivative security	-	6,875 Added 11.5%	52,919 Ordinary Shares
Feb 20 2023	SELL Payment of exercise price or tax liability	$289,289 $28.07 p/Share	10,306 Reduced 18.29%	46,044 Ordinary Shares
Feb 20 2023	BUY Grant, award, or other acquisition	-	22,195 Added 29.69%	52,570 Ordinary Shares
Feb 20 2023	BUY Exercise of conversion of derivative security	-	10,095 Added 22.81%	34,155 Ordinary Shares
Feb 18 2023	SELL Payment of exercise price or tax liability	$74,553 $28.07 p/Share	2,656 Reduced 9.94%	24,060 Ordinary Shares
Feb 18 2023	BUY Exercise of conversion of derivative security	-	8,722 Added 24.61%	26,716 Ordinary Shares
Feb 23 2022	SELL Open market or private sale	$296,699 $24.76 p/Share	11,983 Reduced 39.97%	17,994 Ordinary Shares
Feb 22 2022	SELL Payment of exercise price or tax liability	$88,510 $25.01 p/Share	3,539 Reduced 10.56%	29,977 Ordinary Shares
Feb 22 2022	BUY Exercise of conversion of derivative security	-	12,037 Added 26.42%	33,516 Ordinary Shares
Feb 21 2022	SELL Payment of exercise price or tax liability	$50,712 $25.08 p/Share	2,022 Reduced 8.6%	21,479 Ordinary Shares
Feb 21 2022	BUY Exercise of conversion of derivative security	-	6,875 Added 22.63%	23,501 Ordinary Shares
Feb 20 2022	SELL Payment of exercise price or tax liability	$74,387 $25.08 p/Share	2,966 Reduced 15.14%	16,626 Ordinary Shares

Also insider at

ALBO

ALBIREO PHARMA, INC. Healthcare

Director

CCH